Clinical Trials Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Oct 21, 2015; 21(39): 11168-11178
Published online Oct 21, 2015. doi: 10.3748/wjg.v21.i39.11168
Table 1 Patient characteristics
No.SexAge (yr)LocationSize (mm)MetastasesUICC stageVaccine (times)OS (d)PFS (d)HLA type
Best overall tumor response
HLA-ADRB1DPB1
1M70Body22PeritonitisIV3558244002:0124:0204:0515:0205:0109:01Stable disease
2M68Body15Liver, lymph nodesIV4671720824:0233:0308:0313:0202:0204:01Stable disease
3F49Head18Liver, peritonitis, lymph nodesIV71332602:0124:0204:0509:0102:0205:01Progressive disease
4M35Body25Liver, lymph nodesIV628314702:01-09:0115:0102:0105:01Stable disease
5F72Body22Peritonitis, lymph nodesIV1421510902:0624:0208:0212:0102:0105:01Stable disease
6F69Body-tail45Lymph nodesIV71+1050+54524:0233:0313:0215:0104:0113:01Stable disease
7M39Head-body30PeritonitisIV2032529002:1024:0215:0115:0202:0209:01Stable disease